

Official Document

GENENTECH, INC.

1 DNA Way, South San Francisco, CA 94080-4990

Tel: 650-225-2066 Fax: 650-952-9881

FAX TRANSMISSION COVER SHEET

Date: Thursday, August 17, 2000

To: Examiner Minh Tam Davis

Fax: (703) 308-4426

Tel: (703) 305-2008

Re: U.S.S.N. 09/373,403
Our Ref: P109921

Sender: Deirdre L. Conley

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Pamela Gavette

Type or print name of person signing certification

Pamela Gavette May 14, 2001
Signature Date

**YOU SHOULD RECEIVE 16 PAGE(S), INCLUDING THIS COVER SHEET. IF YOU
DO NOT RECEIVE ALL THE PAGES, PLEASE CALL 650/225-3220**


Comments:

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. This information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

Patent Docket P1099C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of W. Robert Arathoon et al. Serial No.: 09/373,403 Filed: 12 AUGUST 1999 For: A METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS	Group Art Unit: 1642 Examiner: M. Davis CERTIFICATE OF FACSIMILE TRANSMISSION <u>May 14 2001</u> Date of Transmission I hereby certify that this correspondence, consisting of Second Preliminary Amendment, Amendment Transmittal, fax cover sheet is being facsimile transmitted to the Assistant Commissioner of Patents, Washington, D.C. 20231.  Pamela Gavette
--	---

AMENDMENT TRANSMITTALAssistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	20	-	29	0	18	\$0.00
Independent	2	-	4	0	80	\$0.00
Multiple dependent claim(s), if any					270	\$0.00
Total Fee Calculation						\$0.00

X

No additional fee is required.

The Commissioner is hereby authorized to charge Deposit
Account No. 07-0630 in the amount of \$. A duplicate copy of
this transmittal is enclosed.

Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under
37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate
copy of this sheet is enclosed.Respectfully submitted,
GENENTECH, INC.

Date: May 14, 2001

By: 

Deirdre L. Conley, Ph.D

Reg. No. 36,487

Telephone No. (650) 225-2066



09157

PATENT TRADEMARK OFFICE

PowerDocs #90602

Patent Docket P1099C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Robert Arathoon et al.
Serial No.: 09/373,403

Filed: 12 August 1999

For: A METHOD FOR MAKING
MULTISPECIFIC ANTIBODIES
HAVING HETEROMULTIMERIC AND
COMMON COMPONENTS

Group Art Unit: 1642

Examiner: M. Davis

CERTIFICATE OF FACSIMILE TRANSMISSION

May 14, 2001: Date of Transmission

I hereby certify that this correspondence, consisting of
Second Preliminary Amendment, Amendment
Transmittal, fax cover sheet is being facsimile
transmitted to the Assistant Commissioner of Patents,
Washington, D.C. 20231.



Pamela Gavette

SECOND PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application on the merits, please amend the
application as follows:

In the Claims:

Please cancel claims 12-18.

Please add new claims 30-49.

30. A method of preparing a multispecific antibody comprising a first polypeptide and
at least one additional polypeptide, wherein

(a) the first polypeptide comprises a multimerization domain forming an interface
positioned to interact with an interface of a multimerization domain of the additional
polypeptide,

(b) the first and additional polypeptides each comprise a binding domain, the binding
domain comprising a heavy chain and a light chain, wherein the variable light chains of the first

14/K
KJ
5-14-01

Official
ID
5/14/01

C1
23